Compare Biogen Inc (BIIB) vs Allbirds Inc (BIRD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Allbirds Inc — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Allbirds Inc trades at $2.6 (market cap $30.00M). The key difference: Biogen Inc is far larger — about 1004.3× Allbirds Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | BIRD | |
|---|---|---|
Market Cap | $30.13B | $30.00M |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $16.99 |
52-Week Low | $128.93 | $2.21 |
Enterprise Value | $37.20B | $48.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BIRD trades at $2.58, up 1.98% today, amid a strategic pivot from footwear to AI infrastructure, rebranding as Smartbird. Despite negative profitability and cash burn, the stock shows bullish technical signals and surged on recent leadership changes. Revenue has declined from $298M in 2022 to $152M in 2025, with net losses persisting but improving from -$152M to -$77M over the period.
Outlook hinges on successful AI transition, but high execution risk and sustained losses warrant caution. Analysts are mostly neutral, with 79% hold ratings. The stock offers speculative upside if new strategy gains traction, yet faces significant financial and competitive headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
